Long-term outcomes in early relapsing MS improve with first-line...

Multiple Sclerosis News Today

Factuality

Ownership

Long-term outcomes in early relapsing MS improve with first-line...

Using Ocrevus (ocrelizumab) as a first-line treatment for early-stage relapsing forms of multiple sclerosis (MS) is significantly better at delaying disease progression than starting with a less effective drug and switching to Ocrevus later. That’s according to nine years of data from the OPERA I (NCT01247324) and OPERA II (NCT01412333) Phase 3 trials, where participants […] The post First-line Ocrevus may aid early relapsing MS long-term outcom…